Streetbeat News

ABSI

Absci Corporation

https://www.absci.com

Industry

Biotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Open

4.14

Mkt cap

458M

Volume

928K

High

4.22

P/E Ratio

-4.33

52-wk high

6.72

Low

4.01

Div yield

N/A

52-wk low

1.18

Several major stocks, including AMC Networks, Louisiana-Pacific, and others, are experiencing declines in Monday's pre-market session. AMC Networks fell sharply due to a private offering of convertible senior notes, while Louisiana-Pacific was downgraded by Goldman Sachs.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 11:41 am

Ark Invest, led by Cathie Wood, made significant trades involving Robinhood Markets, Moderna, Palantir Technologies, and Advanced Micro Devices. Ark reduced its holdings in Robinhood and Moderna while increasing its positions in Palantir and AMD.

Portfolio Pulse from Benzinga Neuro

May 30, 2024 | 2:57 am

Six analysts have recently shared their insights on Absci (NASDAQ:ABSI), with a mix of bullish and somewhat bullish ratings. The average 12-month price target for Absci is $8.83, reflecting a 26.14% increase from the previous target. Analysts have maintained or raised their ratings, with price targets ranging from $7.00 to $13.00. Despite revenue challenges and below-average ROE and ROA, Absci's net margin and debt management are strong.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 1:00 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 10:47 am

Absci (NASDAQ:ABSI) reported Q1 2024 earnings with a GAAP EPS of $(0.22), missing the $(0.21) estimate, and sales of $898K, missing the $2.419M estimate. This represents a 15.38% decrease in losses per share and a 29.24% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:31 am

BlackBerry Limited announced a collaboration with Advanced Micro Devices, Inc. to enhance next-generation robotic systems, causing its shares to rise 9%. Other stocks like Nurix Therapeutics, Taysha Gene Therapies, and Tesla also saw significant gains due to various factors including strategic collaborations, analyst ratings, and annual reports.

Portfolio Pulse from Avi Kapoor

April 09, 2024 | 2:43 pm

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Absci (NASDAQ:ABSI) and kept the price target at $9.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:17 pm

Six analysts have recently assessed Absci (NASDAQ:ABSI), showing a mix of bullish and somewhat bullish ratings with an average 12-month price target of $8.17, a significant increase from the previous $4.00. Absci, an AI-powered synthetic biology company, has seen a revenue decline of -68.59% over the past 3 months, with a net margin of -2956.18%, ROE of -10.68%, and ROA of -8.97%. Despite the financial challenges, the company's market position remains strong with a low debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:01 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 6:52 pm

Absci (NASDAQ:ABSI) reported Q4 earnings with an EPS of $-0.25, missing estimates by -4.0% and showing a revenue decrease of $1.22 million from the previous year. Despite past earnings misses, the share price increased by 0.0% the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.